JP5060945B2 - 癌診断のためのオリゴヌクレオチド - Google Patents
癌診断のためのオリゴヌクレオチド Download PDFInfo
- Publication number
- JP5060945B2 JP5060945B2 JP2007514130A JP2007514130A JP5060945B2 JP 5060945 B2 JP5060945 B2 JP 5060945B2 JP 2007514130 A JP2007514130 A JP 2007514130A JP 2007514130 A JP2007514130 A JP 2007514130A JP 5060945 B2 JP5060945 B2 JP 5060945B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- cancer
- oligonucleotide
- probes
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims description 138
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims description 71
- 206010028980 Neoplasm Diseases 0.000 title description 185
- 201000011510 cancer Diseases 0.000 title description 161
- 238000003745 diagnosis Methods 0.000 title description 16
- 239000000523 sample Substances 0.000 claims description 295
- 108090000623 proteins and genes Proteins 0.000 claims description 236
- 238000000034 method Methods 0.000 claims description 139
- 230000014509 gene expression Effects 0.000 claims description 110
- 239000002299 complementary DNA Substances 0.000 claims description 71
- 108020004999 messenger RNA Proteins 0.000 claims description 67
- 238000012360 testing method Methods 0.000 claims description 54
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 48
- 239000002751 oligonucleotide probe Substances 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 239000007787 solid Substances 0.000 claims description 37
- 230000000295 complement effect Effects 0.000 claims description 33
- 206010006187 Breast cancer Diseases 0.000 claims description 26
- 208000026310 Breast neoplasm Diseases 0.000 claims description 26
- 238000011835 investigation Methods 0.000 claims description 23
- 238000013518 transcription Methods 0.000 claims description 23
- 230000035897 transcription Effects 0.000 claims description 23
- 230000002441 reversible effect Effects 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 239000002699 waste material Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 93
- 230000000875 corresponding effect Effects 0.000 description 50
- 108090000765 processed proteins & peptides Proteins 0.000 description 48
- 229920001184 polypeptide Polymers 0.000 description 47
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 230000027455 binding Effects 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 38
- 238000004458 analytical method Methods 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 238000002790 cross-validation Methods 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000010238 partial least squares regression Methods 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 239000011159 matrix material Substances 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 238000012544 monitoring process Methods 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 14
- 239000012528 membrane Substances 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- 108010000605 Ribosomal Proteins Proteins 0.000 description 6
- 102000002278 Ribosomal Proteins Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000008857 Ferritin Human genes 0.000 description 5
- 108050000784 Ferritin Proteins 0.000 description 5
- 238000008416 Ferritin Methods 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- -1 proteosome subunit Proteins 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108010077544 Chromatin Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 238000012952 Resampling Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000013145 classification model Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000034286 G proteins Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
- 241000042032 Petrocephalus catostoma Species 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 2
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 2
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003705 background correction Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000012850 discrimination method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 101150066375 35 gene Proteins 0.000 description 1
- 102100024113 40S ribosomal protein S15a Human genes 0.000 description 1
- 102100022600 40S ribosomal protein S3a Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100022406 60S ribosomal protein L10a Human genes 0.000 description 1
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 1
- 102100021690 60S ribosomal protein L18a Human genes 0.000 description 1
- 102100023247 60S ribosomal protein L23a Human genes 0.000 description 1
- 102100021927 60S ribosomal protein L27a Human genes 0.000 description 1
- 101710187898 60S ribosomal protein L28 Proteins 0.000 description 1
- 102100022276 60S ribosomal protein L35a Human genes 0.000 description 1
- 102100031002 60S ribosomal protein L36a Human genes 0.000 description 1
- 102100036126 60S ribosomal protein L37a Human genes 0.000 description 1
- 102100036630 60S ribosomal protein L7a Human genes 0.000 description 1
- 101150037966 67 gene Proteins 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 108010052495 Calgranulin B Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102220519085 Cytochrome P450 1A2_S18C_mutation Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 1
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101150029115 HOPX gene Proteins 0.000 description 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100029242 Hexokinase-2 Human genes 0.000 description 1
- 101710198385 Hexokinase-2 Proteins 0.000 description 1
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 102100028798 Homeodomain-only protein Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000691550 Homo sapiens 39S ribosomal protein L13, mitochondrial Proteins 0.000 description 1
- 101001118566 Homo sapiens 40S ribosomal protein S15a Proteins 0.000 description 1
- 101000755323 Homo sapiens 60S ribosomal protein L10a Proteins 0.000 description 1
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 1
- 101000752293 Homo sapiens 60S ribosomal protein L18a Proteins 0.000 description 1
- 101001115494 Homo sapiens 60S ribosomal protein L23a Proteins 0.000 description 1
- 101001110988 Homo sapiens 60S ribosomal protein L35a Proteins 0.000 description 1
- 101001127203 Homo sapiens 60S ribosomal protein L36a Proteins 0.000 description 1
- 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 description 1
- 101000853243 Homo sapiens 60S ribosomal protein L7a Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 1
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 1
- 101001134134 Homo sapiens Oxidation resistance protein 1 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100029156 Nucleolar protein of 40 kDa Human genes 0.000 description 1
- 101710159068 Nucleolar protein of 40 kDa Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100034219 Oxidation resistance protein 1 Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 101000677219 Schizosaccharomyces pombe (strain 972 / ATCC 24843) 60S ribosomal protein L33-A Proteins 0.000 description 1
- 101000691164 Schizosaccharomyces pombe (strain 972 / ATCC 24843) 60S ribosomal protein L43-A Proteins 0.000 description 1
- 101000732892 Schizosaccharomyces pombe (strain 972 / ATCC 24843) 60S ribosomal protein L8 Proteins 0.000 description 1
- 102220580081 Serrate RNA effector molecule homolog_S18D_mutation Human genes 0.000 description 1
- 102000043912 Sestrin Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100036014 T-cell surface glycoprotein CD1c Human genes 0.000 description 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 1
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000003064 k means clustering Methods 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005312 nonlinear dynamic Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108700020508 sestrin Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920005613 synthetic organic polymer Polymers 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0412301.4A GB0412301D0 (en) | 2004-06-02 | 2004-06-02 | Product and method |
| GB0412301.4 | 2004-06-02 | ||
| PCT/GB2005/002180 WO2005118851A1 (en) | 2004-06-02 | 2005-06-02 | Oligonucleotides for cancer diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501332A JP2008501332A (ja) | 2008-01-24 |
| JP5060945B2 true JP5060945B2 (ja) | 2012-10-31 |
Family
ID=32696533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007514130A Expired - Fee Related JP5060945B2 (ja) | 2004-06-02 | 2005-06-02 | 癌診断のためのオリゴヌクレオチド |
Country Status (17)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006128082A2 (en) * | 2005-05-26 | 2006-11-30 | The Johns Hopkins University | Biomarkers for breast cancer |
| JP2007275027A (ja) * | 2006-04-12 | 2007-10-25 | Fujifilm Corp | 癌関連欠失遺伝子マーカーを用いた癌の診断方法 |
| JP5208477B2 (ja) * | 2007-10-12 | 2013-06-12 | 生化学工業株式会社 | 遺伝子サブトラクション用の担体及びその利用 |
| JP2013511728A (ja) * | 2009-11-20 | 2013-04-04 | ユニバーシティ オブ ルイスビル リサーチ ファンデーション，インコーポレイテッド | 癌のバイオマーカー |
| GB201000688D0 (en) * | 2010-01-15 | 2010-03-03 | Diagenic Asa | Product and method |
| EP3825693A1 (en) * | 2011-04-29 | 2021-05-26 | Cancer Prevention And Cure, Ltd. | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
| CN104822844B (zh) * | 2012-10-01 | 2019-05-07 | 米伦纽姆医药公司 | 预测对抑制剂的反应的生物标记物和方法以及其用途 |
| EP2922971B1 (en) * | 2012-11-20 | 2018-10-17 | Lund, Tore Eiliv | Gene expression profile in diagnostics |
| CA2935232A1 (en) | 2013-12-29 | 2015-07-02 | Curelab Oncology, Inc. | Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases |
| KR20250005391A (ko) * | 2014-06-18 | 2025-01-09 | 도레이 카부시키가이샤 | 식도암의 검출 키트 또는 디바이스 및 검출 방법 |
| FR3029210A1 (fr) | 2014-11-27 | 2016-06-03 | Centre Nat De La Rech Scient (Cnrs) | Methode de pronostic d'hemopathies |
| US10140708B2 (en) * | 2016-01-21 | 2018-11-27 | Riverside Research Institute | Method for gestational age estimation and embryonic mutant detection |
| GB201611738D0 (en) | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| WO2019036388A1 (en) * | 2017-08-14 | 2019-02-21 | Raytheon Company | ALGORITHM OF SUBTRACTION FOR DETECTION OF TUMORS |
| CN109529018B (zh) * | 2019-01-10 | 2021-11-30 | 南方医科大学南方医院 | Atxn2l用于制备逆转胃癌奥沙利铂耐药的药物的用途 |
| CN109596611A (zh) * | 2019-01-21 | 2019-04-09 | 湖北紫荆生物技术有限公司 | 一种水体钙含量测试剂及水体钙含量测量方法 |
| US11475558B2 (en) | 2019-11-13 | 2022-10-18 | Raytheon Company | Organ isolation in scan data |
| US11282209B2 (en) | 2020-01-10 | 2022-03-22 | Raytheon Company | System and method for generating contours |
| US11893745B2 (en) | 2020-12-09 | 2024-02-06 | Raytheon Company | System and method for generating and displaying contours |
| US11562512B2 (en) | 2020-12-09 | 2023-01-24 | Raytheon Company | System and method for generating and displaying contours |
| CN113913436B (zh) * | 2021-11-18 | 2023-09-29 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 逆转录转座基因l1-atp8b1及其作为肺鳞癌标志物的用途和治疗肺鳞癌的药物 |
| CN115976212B (zh) * | 2022-12-21 | 2024-06-11 | 四川大学华西医院 | 一种用于检测骨肿瘤诊断相关基因的探针库及试剂盒 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981783A (en) * | 1986-04-16 | 1991-01-01 | Montefiore Medical Center | Method for detecting pathological conditions |
| US5925525A (en) * | 1989-06-07 | 1999-07-20 | Affymetrix, Inc. | Method of identifying nucleotide differences |
| US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5871928A (en) * | 1989-06-07 | 1999-02-16 | Fodor; Stephen P. A. | Methods for nucleic acid analysis |
| US6040138A (en) * | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| JP2802125B2 (ja) | 1989-06-23 | 1998-09-24 | キヤノン株式会社 | 核酸の検出方法 |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| ATE143700T1 (de) | 1991-09-23 | 1996-10-15 | Pfizer | Verfahren für die detektion von spezifische mrns und dns in zellen |
| GB2260811B (en) | 1991-10-23 | 1995-07-05 | Yorkshire Cancer Research Camp | Detection of malignant tumours |
| WO1993018143A1 (en) | 1992-03-04 | 1993-09-16 | Synaptic Pharmaceutical Corporation | Dna encoding taurine and gaba transporters and uses thereof |
| US6114114A (en) | 1992-07-17 | 2000-09-05 | Incyte Pharmaceuticals, Inc. | Comparative gene transcript analysis |
| US5633137A (en) * | 1992-12-01 | 1997-05-27 | The University Of South Florida | Method for measuring specific gene expression: transcriptional activity per gene dose |
| US5677125A (en) * | 1994-01-14 | 1997-10-14 | Vanderbilt University | Method of detection and diagnosis of pre-invasive cancer |
| US5830645A (en) * | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5545531A (en) * | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US6156502A (en) | 1995-12-21 | 2000-12-05 | Beattie; Kenneth Loren | Arbitrary sequence oligonucleotide fingerprinting |
| AU2253397A (en) | 1996-01-23 | 1997-08-20 | Affymetrix, Inc. | Nucleic acid analysis techniques |
| JP2000504575A (ja) | 1996-02-08 | 2000-04-18 | アフィメトリックス，インコーポレイテッド | 微生物のチップベースの種分化および表現型特徴付け |
| AU4327697A (en) | 1996-08-20 | 1998-03-06 | Motorola, Inc. | Method and apparatus for detecting predetermined molecular structures in a sample |
| US6235474B1 (en) | 1996-12-30 | 2001-05-22 | The Johns Hopkins University | Methods and kits for diagnosing and determination of the predisposition for diseases |
| US6190857B1 (en) * | 1997-03-24 | 2001-02-20 | Urocor, Inc. | Diagnosis of disease state using MRNA profiles in peripheral leukocytes |
| NO972006D0 (no) * | 1997-04-30 | 1997-04-30 | Forskningsparken I Aas As | Ny metode for diagnose av sykdommer |
| US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| AU9071098A (en) | 1997-07-29 | 1999-02-22 | Lambert C. J. Dorssers | Breast cancer resistance genes, methods for their detection and uses thereof |
| US6607879B1 (en) * | 1998-02-09 | 2003-08-19 | Incyte Corporation | Compositions for the detection of blood cell and immunological response gene expression |
| US6174680B1 (en) * | 1998-12-30 | 2001-01-16 | Dana-Farber Cancer Institute, Inc. | Method for identifying mismatch repair glycosylase reactive sites, compounds and uses thereof |
| ATE347102T1 (de) | 1998-02-25 | 2006-12-15 | Us Health | Zellulare anordnungen für schnelle molekulare profilidentifizierung |
| US6004755A (en) * | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6696246B1 (en) | 1998-08-21 | 2004-02-24 | Naxcor, Inc. | Assays using crosslinkable immobilized nucleic acids |
| US20080261292A1 (en) * | 1998-09-22 | 2008-10-23 | Oncomedx, Inc. | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions |
| US6593084B2 (en) | 1998-10-13 | 2003-07-15 | Robert E. Bird | Carcinogen assay |
| EP1121471A1 (en) | 1998-10-13 | 2001-08-08 | Clontech Laboratories, Inc. | Nucleic acid arrays |
| EP1131470A4 (en) | 1998-10-28 | 2004-11-10 | Vysis Inc | CELLULAR NETWORKS AND METHODS FOR DETECTION AND USE OF GENETIC DISORDER MARKERS |
| WO2000026412A1 (en) | 1998-11-02 | 2000-05-11 | Kenneth Loren Beattie | Nucleic acid analysis using sequence-targeted tandem hybridization |
| AU1853600A (en) | 1999-01-06 | 2000-07-24 | Choong-Chin Liew | Method for the detection of gene transcripts in blood and uses thereof |
| US20040241728A1 (en) * | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of lung disease related gene transcripts in blood |
| US7473528B2 (en) * | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
| US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US20050003394A1 (en) * | 1999-01-06 | 2005-01-06 | Chondrogene Limited | Method for the detection of rheumatoid arthritis related gene transcripts in blood |
| US20040248169A1 (en) * | 1999-01-06 | 2004-12-09 | Chondrogene Limited | Method for the detection of obesity related gene transcripts in blood |
| US20040265868A1 (en) * | 1999-01-06 | 2004-12-30 | Chondrogene Limited | Method for the detection of depression related gene transcripts in blood |
| US20040265869A1 (en) * | 1999-01-06 | 2004-12-30 | Chondrogene Limited | Method for the detection of type II diabetes related gene transcripts in blood |
| US20040241727A1 (en) * | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of schizophrenia related gene transcripts in blood |
| US20050042630A1 (en) * | 1999-01-06 | 2005-02-24 | Chondrogene Limited | Method for the detection of asthma related gene transcripts in blood |
| US20040241726A1 (en) * | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of allergies related gene transcripts in blood |
| US20040248170A1 (en) * | 1999-01-06 | 2004-12-09 | Chondrogene Limited | Method for the detection of hyperlipidemia related gene transcripts in blood |
| DE19937187A1 (de) * | 1999-08-06 | 2001-03-01 | Qiagen Gmbh | Automatisierte Proteinreinigung im Multiwellformat durch Vakuumfiltration |
| WO2002008765A2 (en) * | 2000-07-26 | 2002-01-31 | Stanford University | Basal cell markers in breast cancer and uses thereof |
| US7108969B1 (en) * | 2000-09-08 | 2006-09-19 | Affymetrix, Inc. | Methods for detecting and diagnosing oral cancer |
| US6955876B2 (en) * | 2000-11-01 | 2005-10-18 | Kane Michael D | Compositions and systems for identifying and comparing expressed genes (mRNAs) in eukaryotic organisms |
| WO2002059367A2 (en) | 2000-11-30 | 2002-08-01 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis |
| JP4368110B2 (ja) * | 2001-01-12 | 2009-11-18 | エール ユニヴァーシティ | 癌患者の生物学的流体中のサバイビンの検出 |
| US20020132274A1 (en) * | 2001-01-17 | 2002-09-19 | Nevalainen Marja T. | Diagnostic and monitorings methods for cancer |
| AU2002253878A1 (en) * | 2001-01-25 | 2002-08-06 | Gene Logic, Inc. | Gene expression profiles in breast tissue |
| WO2002070737A2 (en) | 2001-02-28 | 2002-09-12 | Chondrogene Inc. | Compositions and methods relating to osteoarthritis |
| EP1384079A2 (en) * | 2001-05-02 | 2004-01-28 | Oxford GlycoSciences (UK) Limited | Proteins, genes and their use for diagnosis and treatment of breast cancer |
| US20020169560A1 (en) * | 2001-05-12 | 2002-11-14 | X-Mine | Analysis mechanism for genetic data |
| US7335467B2 (en) * | 2001-05-15 | 2008-02-26 | Ludwig Institute For Cancer Research | Breast cancer antigens |
| US20030036077A1 (en) * | 2001-05-31 | 2003-02-20 | Chronix Biomedical | Methods for generating an mRNA expression profile from an ecellular mRNA containing blood sample and using the same to identify functional state markers |
| US7297480B2 (en) * | 2001-06-28 | 2007-11-20 | Dermtech International | Method for detection of melanoma |
| WO2003008963A1 (en) * | 2001-07-18 | 2003-01-30 | University Of Louisville Research Foundation, Inc. | E-genechip online web service for data mining bioinformatics |
| US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US7622260B2 (en) * | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| CA2466483A1 (en) * | 2001-11-07 | 2003-07-03 | John D. Shaughnessy | Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| US20030232350A1 (en) * | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003041562A2 (en) * | 2001-11-14 | 2003-05-22 | Whitehead Institute For Biomedical Research | Molecular cancer diagnosis using tumor gene expression signature |
| AU2002361908A1 (en) * | 2001-12-31 | 2003-07-24 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
| US20030195431A1 (en) * | 2002-04-10 | 2003-10-16 | Sukhatme Vikas P. | Observation of effects of body fluids on indicator cells for disease diagnosis |
| WO2003100000A2 (en) * | 2002-05-24 | 2003-12-04 | Tularik Inc. | Amplification and overexpression of oncogenes |
| US20060281081A1 (en) * | 2002-08-30 | 2006-12-14 | Yusuke Nakamura | Method of diagnosing colon and gastric cancers |
| EP1581652A4 (en) | 2002-09-12 | 2008-02-13 | Genenews Corp | IDENTIFICATION OF SEQUENCES PARTICULAR USEFUL IN THE DIAGNOSIS AND IDENTIFICATION OF THERAPEUTIC TARGETS FOR OSTEO ARTHRITIS |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| GB0227238D0 (en) * | 2002-11-21 | 2002-12-31 | Diagenic As | Product and method |
| US7910550B2 (en) * | 2004-04-16 | 2011-03-22 | Stc.Unm | Human kunitz-type inhibitor with enhanced antifibrinolytic activity |
| EP1809765A2 (en) * | 2004-11-04 | 2007-07-25 | Roche Diagnostics GmbH | Classification of acute myeloid leukemia |
| US20070178503A1 (en) * | 2005-12-19 | 2007-08-02 | Feng Jiang | In-situ genomic DNA chip for detection of cancer |
-
2004
- 2004-06-02 GB GBGB0412301.4A patent/GB0412301D0/en not_active Ceased
-
2005
- 2005-06-02 EP EP05747218A patent/EP1766056B1/en not_active Expired - Lifetime
- 2005-06-02 DK DK05747218.5T patent/DK1766056T3/da active
- 2005-06-02 AT AT05747218T patent/ATE493511T1/de not_active IP Right Cessation
- 2005-06-02 CN CN200580026265.8A patent/CN101027410A/zh active Pending
- 2005-06-02 JP JP2007514130A patent/JP5060945B2/ja not_active Expired - Fee Related
- 2005-06-02 SI SI200531251T patent/SI1766056T1/sl unknown
- 2005-06-02 CA CA002568889A patent/CA2568889A1/en not_active Abandoned
- 2005-06-02 WO PCT/GB2005/002180 patent/WO2005118851A1/en active Application Filing
- 2005-06-02 DE DE602005025633T patent/DE602005025633D1/de not_active Expired - Lifetime
- 2005-06-02 NZ NZ551797A patent/NZ551797A/en not_active IP Right Cessation
- 2005-06-02 ES ES05747218T patent/ES2358910T3/es not_active Expired - Lifetime
- 2005-06-02 ZA ZA200610644A patent/ZA200610644B/en unknown
- 2005-06-02 AU AU2005250219A patent/AU2005250219B2/en not_active Ceased
- 2005-06-02 US US11/628,300 patent/US8105773B2/en not_active Expired - Fee Related
- 2005-06-02 AP AP2006003862A patent/AP2006003862A0/xx unknown
-
2006
- 2006-12-20 NO NO20065939A patent/NO20065939L/no not_active Application Discontinuation
-
2012
- 2012-01-05 US US13/344,088 patent/US20120295800A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005250219B2 (en) | 2011-01-20 |
| US20120295800A1 (en) | 2012-11-22 |
| ATE493511T1 (de) | 2011-01-15 |
| US20080026385A1 (en) | 2008-01-31 |
| GB0412301D0 (en) | 2004-07-07 |
| EP1766056A1 (en) | 2007-03-28 |
| ES2358910T3 (es) | 2011-05-16 |
| CA2568889A1 (en) | 2005-12-15 |
| US8105773B2 (en) | 2012-01-31 |
| NZ551797A (en) | 2010-03-26 |
| DK1766056T3 (da) | 2011-03-14 |
| CN101027410A (zh) | 2007-08-29 |
| DE602005025633D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2011-02-10 |
| AU2005250219A1 (en) | 2005-12-15 |
| AP2006003862A0 (en) | 2006-12-31 |
| NO20065939L (no) | 2007-02-08 |
| ZA200610644B (en) | 2008-07-30 |
| JP2008501332A (ja) | 2008-01-24 |
| EP1766056B1 (en) | 2010-12-29 |
| SI1766056T1 (sl) | 2011-05-31 |
| WO2005118851A1 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5060945B2 (ja) | 癌診断のためのオリゴヌクレオチド | |
| US10697975B2 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
| Kallioniemi | Biochip technologies in cancer research | |
| JP2013516968A (ja) | 診断用遺伝子発現プラットフォーム | |
| US20200347444A1 (en) | Gene-expression profiling with reduced numbers of transcript measurements | |
| EP2556185B1 (en) | Gene-expression profiling with reduced numbers of transcript measurements | |
| EP2121988B1 (en) | Prostate cancer survival and recurrence | |
| JP2010527577A (ja) | 検出方法 | |
| CA2505151C (en) | Status determination | |
| Cobb et al. | Injury in the era of genomics | |
| CN107960106B (zh) | 用于增强的cgh分析的方法、载体和试剂盒 | |
| ES2342161T3 (es) | Producto y metodo. | |
| US20180051342A1 (en) | Prostate cancer survival and recurrence | |
| WO2005030959A1 (ja) | 神経芽細胞腫予後診断のためのマイクロアレイと神経芽細胞腫予後診断方法 | |
| Budhraja et al. | Microarray analysis of trophoblast cells | |
| Westbrook | Novel Targets for the Diagnosis and Treatment of Breast Cancer Identified by Genomic Analysis | |
| HK1179311B (en) | Gene-expression profiling with reduced numbers of transcript measurements | |
| HK1179311A (en) | Gene-expression profiling with reduced numbers of transcript measurements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101118 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120203 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120413 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120601 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120717 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120806 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150810 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |